Skip to search formSkip to main contentSkip to account menu

Anti-NaPi2b/MMAE Antibody-Drug Conjugate DNIB0600A

Known as: ADC DNIB0600A, DNIB0600A 
An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the sodium-dependent phosphate transport protein 2B (NaPi2b), and… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A randomized, open-label, phase II study of anti-NaPi2b antibody-drug conjugate (ADC) lifastuzumab (Lifa) vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin (PLD) in patients (pts) with…
5569Background: NaPi2b is a transmembrane, sodium-dependent phosphate transporter expressed in ~90% of OC. Lifa, a humanized anti… 
2015
2015
Abstract POSTER-THER-1441: Biomarker evaluation of phase 1 clinical trials of antibody-drug conjugates (ADCs) in platinum resistant ovarian cancer
Purpose: DNIB0600A and DMUC5754A are two ADCs that conjugate the anti-mitotic agent MMAE with anti-NaPi2b and anti-MUC16… 
2009
2009
Épitope napi2b (slc34a2) de transport à travers les membranes pour une thérapie par anticorps, anticorps dirigés contre celui-ci, et cible pour une thérapie du cancer
La presente invention porte d'une maniere generale sur le transporteur membranaire NaPi2b (SLC34A2) comme cible pour une therapie… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)